USD10
Acciones de CLYM
Acerca de Climb BioClimb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
USD10
Acciones de CLYM
Acerca de Climb BioClimb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Estadísticas
VENTANA DE TRADING
Cerrado
ABRE A LAS
23 mar at 13:30 GMT+0
CAP. DE MERCADO
299,98 M US$
PRECIO DE APERTURA
No hay datos suficientes
MÍNIMO (1 A)
1,05 US$
MÁXIMO (1 A)
8,04 US$
MÍNIMO (24 h)
6,28 US$
MÁXIMO (24 h)
6,28 US$
VOLUMEN (24 h)
1,00 US$
100 %
Historial de precios
Time | Price | Change |
|---|---|---|
Hoy | No hay datos suficientes | No hay datos suficientes |
1 día | 6,28 US$ | 0,00 % |
1 semana | 7,07 US$ | |
1 mes | 5,65 US$ | |
1 año | 1,32 US$ |